SOPHiA GENETICS SA SOPH PHARMA
Company Overview
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom and a collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The company was incorporated in 2011 and is based in Rolle, Switzerland.
Why Investors Should Care
Revenue has grown at a 17.6% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $77.27M (+18.6% YoY); net profit $-79.00M.
- Trailing 12 Months Year-on-year growth — revenue +27.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 17.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 17.56% |
| 1 Year: | 27.20% |
Stock Price Performance
| 1 Year: | +168.81% |
| 6 Months: | +87.44% |
| 3 Months: | +58.33% |
| 1 Month: | +8.43% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.75 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 17.6% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SOPH SOPHiA GENETICS SA PHARMA | 8.36 | -7.21 | $711.67M | 0.00% | -63.03% | -101.22% | 17.56% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 17.78M | 18.32M | 19.46M | 21.71M | 21.69M |
| Cost of Revenue | - | 5.57M | 6.05M | 6.55M | 7.01M | 6.94M |
| Gross Profit | - | 12.21M | 12.27M | 12.91M | 14.69M | 14.75M |
| Operating Expenses | - | 28.24M | 30.76M | 30.77M | 33.21M | 32.03M |
| Operating Income | - | -16.04M | -18.49M | -17.86M | -18.52M | -17.28M |
| EBITDA | - | -13.93M | -18.72M | -15.29M | -15.46M | -14.65M |
| Interest Expense | - | 659.00K | 559.00K | 1.66M | 1.67M | 1.67M |
| Pretax Income | - | -16.88M | -21.65M | -19.38M | -19.57M | -19.07M |
| Tax Provision | - | 503.00K | 762.00K | 642.00K | -395.00K | 253.00K |
| Net Income | - | -17.39M | -22.41M | -20.02M | -19.18M | -19.32M |
| Diluted EPS | - | -0.26 | -0.33 | -0.30 | -0.28 | -0.27 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 47.56M | 62.37M | 65.17M | 77.27M |
| Cost of Revenue | 16.31M | 19.46M | 21.24M | 25.19M |
| Gross Profit | 31.25M | 42.91M | 43.94M | 52.08M |
| Operating Expenses | 119.08M | 117.74M | 110.50M | 122.98M |
| Operating Income | -87.82M | -74.83M | -66.57M | -70.91M |
| EBITDA | -81.38M | -69.57M | -50.76M | -63.40M |
| Interest Expense | 639.00K | 588.00K | 1.91M | 4.55M |
| Pretax Income | -87.58M | -78.50M | -61.27M | -77.49M |
| Tax Provision | -136.00K | 486.00K | 1.22M | 1.51M |
| Net Income | -87.45M | -78.98M | -62.49M | -79.00M |
| Diluted EPS | -1.36 | -1.22 | -0.95 | -1.17 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 243.84M | 206.16M | 155.31M | 163.03M |
| Current Assets | - | 196.25M | 148.05M | 99.41M | 99.08M |
| Cash & Equivalents | - | 161.31M | 123.25M | 80.23M | 70.29M |
| Inventory | - | 5.16M | 6.48M | 5.87M | 6.35M |
| Receivables | - | 6.06M | 10.26M | 7.09M | 14.40M |
| Total Liabilities | - | 43.71M | 54.71M | 58.82M | 115.89M |
| Current Liabilities | - | 26.81M | 35.62M | 26.80M | 50.53M |
| Long Term Debt | - | - | - | 13.24M | 47.73M |
| Total Debt | - | 16.74M | 18.60M | 30.03M | 63.02M |
| Total Equity | - | 200.13M | 151.44M | 96.49M | 47.15M |
| Shares Outstanding | - | 66.40M | 76.90M | 79.32M | 89.32M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -70.09M | -53.22M | -44.52M | -35.89M |
| Investing Cash Flow | - | 41.97M | 12.97M | -4.75M | -8.67M |
| Financing Cash Flow | - | -1.57M | -2.82M | 9.86M | 30.18M |
| Capital Expenditure | - | -10.38M | -9.23M | -8.18M | -8.62M |
| Free Cash Flow | - | -80.47M | -62.45M | -52.69M | -44.51M |
| Net Change in Cash | - | -29.69M | -43.07M | -39.41M | -14.39M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 65.7% | 68.8% | 67.4% | 67.4% |
| Operating Margin % | -184.7% | -120.0% | -102.1% | -91.8% |
| Net Margin % | -183.9% | -126.6% | -95.9% | -102.2% |
| ROE % | -43.7% | -52.2% | -64.8% | -167.6% |
| ROCE % | -40.5% | -43.9% | -51.8% | -63.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Generation Investment Management LLP | 8.09% | 6.79M | $55.61M |
| 2 | AIGH Capital Management LLC | 4.71% | 3.95M | $32.38M |
| 3 | Akre Capital Management, LLC | 4.43% | 3.72M | $30.46M |
| 4 | Royce & Associates LP | 4.03% | 3.38M | $27.70M |
| 5 | Principal Financial Group, Inc. | 2.82% | 2.36M | $19.36M |
| 6 | Ameriprise Financial, Inc. | 2.64% | 2.22M | $18.16M |
| 7 | Banque Pictet & Cie SA | 2.63% | 2.21M | $18.09M |
| 8 | AWM Investment Company, Inc. | 2.03% | 1.70M | $13.92M |
| 9 | Soleus Capital Management, L.P. | 1.87% | 1.56M | $12.82M |
| 10 | Silvercrest Asset Management Group, LLC | 1.70% | 1.43M | $11.70M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SOPH
SOPHiA GENETICS (SOPH) Stock Sees Modest Fair Value Lift After Q2 Guidance Raise - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNMGJrU2N0UzhIYXVDb1ZNbGRrWDBGZVlLYkd6SzhJdHBLTWVSS1dtLWJ6alJSckhiMFJ0S0NTU0ZMRVpyNE82RkFVYUNhZ3FVS1BJVXRuUzhNellYbDZRbGp3S3dJRlRINHYwSzVPY0M1WWt4ZnlwY1dDVklNR3ltdVprb0t3TjRta1hnUD…
SOPHiA GENETICS (NASDAQ:SOPH) Stock Price Down 5% - Here's Why - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPNGtpNVp5aU1veGM2anpFNXhmSk10QXJhcUx3dnJfV3pkSjYtajdCaUdLWVBGeEtfVHVYZmVKU3R5QVhqMzNzZTBub3NOMl83bjMyMU5Dd1dNeEdVZWJSeU9Vb2hkZjhvSFZYaXVOLURqRVY2eDJ3TUxVdHpPRmFrOHptbElSNk9GLUtCZ2…
Behavioral Patterns of SOPH and Institutional Flows - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxObEZaaGM1X3V2NVFQalhyelF6N192N0dUd2Z2bW5IT0Exb3BBZk9vZXd3U21QNFB1VGZlR0pBSmpyZjNzT3pTTzhVdEVEcFNYWjhpU1ZGaVJlZDRoWWFIT2h2UWZudWZCZUVUdGQ1bEktbjZMSVk0aUN3X2lTRk5Bd3JGWTJZbUFiZHJqU1…
SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares - PR Newswire
<a href="https://news.google.com/rss/articles/CBMivAJBVV95cUxNVF9BcWl4V1hXWjN1Z1NuRzEzcXF0dXFjR1kzdTFObk41ZW1ENXJfbjZCVTVBSGhOQzNFUHhwMXJIeGFxdFBwenF0QlhoWVhEWVdsNEM1b21IaTRNN004aWZRal9QM0dDZUhkOGNzMm9fTnZrYnJTb1RnTUhRUkNvN0x4eFQxTGx1X0xJek…
$SOPH ($SOPH) Releases Q2 2026 Earnings | SOPH Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxQU2Y5V21hVjU4NzVqek1EUDVpS0N1TzlUWV9GTE1aU1RHbWttR1ZNRzVRY19NWWV4Ujl3RE1sMXdWYjM3MDc3bV94aXdkaEJtRl9qSm1yby1TVjJyUW40amFsc1d2dTR1aDZtSm9xOEdPMUptQU5jcVZ1STN3OHNHM1dULUdDOHc?oc=5" …
SOPH Stock Heads For Best Day In Over 8 Months – What’s Driving Today’s Super Rally? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxQNy0zUkFxM2doUmJpb0hTMlBHd3ktbm05ZXV6LWpyTUJSb3M5cjN0cENmck44NlVnZElJRUlBalg4M2Zwd2hzSFJGX0tBU1ZQWHFQSURwQWVyZC13X0kydUdoaVZYRnJ1ZTUtZVdwWER1QUI5YXQtdFNycHJGSTlia1h0TmFHRkQzdHI2cz…
SOPH — Frequently Asked Questions
What is the current share price of SOPHiA GENETICS SA (SOPH)?
As of 2026-09-19 21:16 PDT, SOPHiA GENETICS SA (SOPH) trades at $8.36 on NasdaqGS. Its 52-week range is $3.11 to $8.92.
What is the market capitalisation of SOPH?
SOPHiA GENETICS SA (SOPH) has a market capitalisation of $711.67M on NasdaqGS.
What is the P/E ratio of SOPH?
SOPH trades at a trailing price-to-earnings (P/E) ratio of -7.21. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 8.39.
What is the return on equity (ROE) of SOPH?
SOPH has a return on equity (ROE) of -101.22%. Its return on capital employed (ROCE) is -63.03%.
Is SOPH a good stock to buy?
This page provides a data-driven analysis of SOPHiA GENETICS SA (SOPH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.